Prenetics Global Q2 revenue jumps on AI brand growth

Prenetics Global

18/08/2026 12:38

Overview
Consumer health company's Q2 revenue rose about 288% yr/yr, driven by IM8 brand growth
IM8 revenue marked sixth consecutive record quarter, with July as strongest month ever
Company achieved positive adjusted free cash flow for first time and raised full-year guidance

Outlook
Prenetics raises 2026 total revenue guidance to $220-230 mln
Company initiates 2027 IM8 revenue guidance of $400 mln or more
Prenetics expects consolidated adjusted free cash flow to remain positive

Result Drivers
IM8 BRAND GROWTH - IM8 drove Q2 results, marking sixth consecutive record quarter, per CEO Danny Yeung
RECORD JULY - July was IM8's strongest month ever, reaching $20.9 mln in revenue, per company statement
POSITIVE CASH FLOW - Company achieved positive adjusted free cash flow for first time, expects it to remain positive, per CEO Danny Yeung

Company press release: ID:nGNXbCC5NC

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$46.50 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Prenetics Global Ltd is $30.00, about 54.9% above its August 17 closing price of $19.37

Reuters Recommended Reads
Aug 18 - China's Ping An Healthcare H1 revenue profit jumps on corporate client base expansion
Aug 17 - Vaccine maker Sinovac H1 revenue rises on overseas growth, approvals
Aug 17 - Mobile healthcare provider DocGo's Q2 revenue misses on wind-down of migrant programs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)